EU & US Skincare Regulation Watch: What Brands Need to Plan for in 2026–2027

Regulation is now a product-development input, not a final packaging check. A formula that is commercially attractive can still miss its launch window if the responsible person, safety file, notification, claim substantiation, packaging evidence or facility records are not planned early.

This watch covers the EU, United States and Great Britain—the three systems most likely to shape an international skincare brief. It is a practical planning guide, not legal advice; final market entry needs review by the responsible local regulatory team.

Original visual: a cosmetics compliance and formulation-development concept.

Executive Summary

• EU: the responsible person, safety assessment, Product Information File (PIF), notification and substantiated claims remain the core launch framework. European Commission
• United States: MoCRA adds facility registration, product listing, serious adverse-event reporting and records responsibilities, subject to defined exemptions. FDA
• Great Britain: a UK-established Responsible Person, SCPN notification, safety assessment and label information are required before products are made available in GB. GOV.UK
• EU microplastics: transition dates are already relevant to formula and packaging planning: rinse-off cosmetics to 16 October 2027, leave-on cosmetics to 16 October 2029, and certain make-up/lip/nail products to 16 October 2035. European Commission

Why Compliance Has Moved Upstream

The same serum can require different operational evidence in the EU, US and UK. Ingredient selection affects safety assessment and substantiation; packaging affects labels and stability; promotional copy determines whether a product remains in cosmetic territory. The practical answer is a market-entry brief prepared at concept stage, not after mass production.

EU, US and UK: Launch-Readiness Comparison

The EU system centres on a Responsible Person, product safety report/PIF and CPNP notification. EU claims may not imply characteristics or functions the product does not have, and the Commission provides common criteria for claim justification. EU cosmetics legislation

In the US, MoCRA requires manufacturers/processors to register facilities and renew every two years, while responsible persons list marketed cosmetic products and update information annually. It also requires serious adverse-event reporting and recordkeeping; defined small-business exemptions exist. FDA MoCRA

For Great Britain, the UK Responsible Person must ensure safety, maintain a PIF, notify via SCPN before market availability and support product claims. GOV.UK

EU Microplastics: Dates That Change Formula Decisions

The restriction applies to synthetic polymer microparticles and has category-specific transition periods. This should trigger a bill-of-materials review, supplier declarations, reformulation timeline and claim/label review now—not in the final month before a deadline.

Claims: What Brands Can Say vs What Creates Risk

This table does not replace claim review. It shows why ingredients such as exosomes, PDRN, peptides, acids and NAD+ need a formula-specific evidence package and restrained copy.

Ingredient Categories Requiring Extra Planning

• Microplastics and polymers: identify intentionally added synthetic polymer microparticles and applicable EU transition periods.
• Nanomaterials: EU rules require notification and ingredient-list labelling where applicable; novel nanomaterials have additional timing requirements in GB. GOV.UK guidance
• Clinic-inspired actives: exosomes, PDRN and advanced peptides must not inherit therapeutic or procedure claims from unrelated studies.
• Acids, retinoid systems and sunscreens: use market-specific permitted-use, warning, testing and claim pathways rather than assuming one global brief works everywhere.

What This Means for Global Product Planning

Build one evidence core, then localise the requirements around it. The central file should include INCI and supplier documentation, formula specifications, stability and compatibility results, safety evidence, manufacturing records, label copy, claim substantiation and adverse-event contact route. The EU/UK responsible-person and notification work, US facility/product obligations and local advertising review should then be planned in parallel.

Three OEM/ODM Actions for This Quarter

1. Create a market-specific formula screen. Check ingredient identity, restrictions, microplastics exposure, nanomaterial status and intended markets before finalising samples.
2. Write claims with the test plan. Define the cosmetic benefit first, then select relevant instrumental, consumer-perception or clinical testing for the finished formula.
3. Pre-review the pack and records. Confirm responsible-person details, notification inputs, mandatory label data, batch traceability, stability evidence and adverse-event handling before artwork is locked.

For a compliance-oriented development brief, brands can review ZD Cosmetic Ingredients, the Ingredient Library and OEM/ODM service.

Conclusion

The most resilient product-development plan treats compliance as a design constraint that improves launch quality. EU, US and UK rules do not demand the same records, but all reward clear ingredients, accurate labels, substantiated cosmetic claims and traceable safety processes. Start those decisions while the formula is still flexible.

To discuss a target market, formula direction and claim plan, contact the ZD team.

Sources and Evidence Notes

• European Commission, Regulation (EC) No 1223/2009 and cosmetics legislation guidance, accessed September 2026.
• European Commission, Regulation (EU) 2023/2055 microplastics restriction guidance, accessed September 2026.
• FDA, Modernization of Cosmetics Regulation Act of 2022 (MoCRA), accessed September 2026.
• UK Department for Business and Trade / OPSS, cosmetics product notification and Great Britain market guidance, accessed September 2026.

Scope note: This article summarises public regulatory guidance for product-planning purposes. It does not replace jurisdiction-specific legal, safety-assessor or Responsible Person advice.